文献速递创伤与烧伤重症综合管理与镇静镇痛

新型创伤复合评分在预测各年龄段死亡率方面优于损伤严重度评分

Novel Trauma Composite Score is superior to Injury Severity Score in predicting mortality across all ages.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论基于年龄的创伤复合评分(TCS)在钝性和穿透性创伤中预测死亡率均优于ISS,尤其对老年和穿透伤患者。

该研究从2010-2016年美国国家创伤数据库纳入777,794例成人钝性(91.1%)或穿透性(8.9%)创伤患者,排除生命体征不完整/非生理性者。为每个年龄构建基于AIS、GCS、生命体征和性别的创伤复合评分(TCS),并与ISS、ISS>16、TRISS和RTS比较死亡率预测。结果显示TCS在所有年龄段和创伤类型中预测死亡率均更准确(AUC比较p<0.001)。ISS对老年人和穿透性创伤患者的死亡率预测能力较差。

要点

  • 在全部钝性和穿透性创伤队列中,预测死亡率的最佳ISS切点为16。
  • 对于<70岁钝性创伤患者,最佳ISS切点在20-25之间;>70岁者最佳ISS随年龄增长而稳步下降。
  • 穿透性创伤所有年龄段的ISS切点均为≤16。
  • TCS在所有年龄段、钝性和穿透性创伤中预测死亡率均优于ISS、ISS>16、TRISS和RTS(AUC比较p<0.001)。
  • ISS对老年患者和穿透性创伤患者的死亡率预测能力较差。

适用人群与场景

  • 成人(≥18岁)钝性创伤或穿透性创伤患者,数据来自2010-2016年国家创伤数据库。
  • 排除生命体征不完整或非生理性者。

诊断标准与关键阈值

  • 预测死亡率的最佳ISS切点:全部钝性和穿透性创伤队列为16;<70岁钝性创伤为20-25;>70岁钝性创伤随年龄增长而下降;穿透性创伤所有年龄段≤16。
  • TCS基于AIS评分、GCS、生命体征和性别中显著(p<0.05)变量按年龄构建。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性数据库分析;样本量777,794例;数据来源:2010-2016年国家创伤数据银行。
  • 人群:成人钝性创伤91.1%,穿透性创伤8.9%;钝性创伤患者更年长(53.6±21.3岁 vs 34.4±13.8岁),ISS更高(11.1±8.5 vs 8.5±8.9),死亡率更低(2.9% vs 3.4%)(p<0.05)。
  • 干预/方法:为每个年龄通过切点分析确定预测死亡率最佳ISS,并用线性判别分析比较ISS、ISS>16、TRISS和RTS;用AIS、GCS、生命体征和性别中显著变量构建TCS。
  • 主要终点结果:TCS在所有年龄段、钝性和穿透性创伤中预测死亡率均优于其他评分系统(AUC比较p<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性数据库研究;证据等级:临床结局,Level IV。
  • 局限:回顾性设计;基于国家创伤数据库;需外部验证。

对床旁实践的改变

  • 在创伤死亡率预测中,不应仅依赖ISS,尤其对老年患者和穿透性创伤患者。
  • 可考虑使用基于年龄的TCS替代ISS进行死亡率风险分层,但需注意TCS为研究推导指标,尚未在床旁前瞻性验证。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Injury Severity Score (ISS) is a widely used metric for trauma research and center verification; however, it does not account for age-related physiologic parameters. We hypothesized that a novel age-based injury severity metric would better predict mortality.

METHODS: Adult patients (≥18 years) sustaining blunt trauma (BT) or penetrating trauma (PT) were abstracted from the 2010 to 2016 National Trauma Data Bank. Admission vitals, Glasgow Coma Scale, ISS, mechanism, and outcomes were analyzed. Patients with incomplete/non-physiologic vital signs were excluded. For each age: (1) a cut point analysis was used to determine the ISS with the highest specificity and sensitivity for predicting mortality and (2) a linear discriminant analysis was performed using ISS, ISS greater than 16, Trauma and Injury Severity Score, and Revised Trauma Scale to compare each scoring system's mortality prediction. A novel injury severity metric, the trauma component score (TCS), was developed for each age using significant (p < 0.05) variables selected from Abbreviated Injury Scale scores, Glasgow Coma Scale, vital signs, and gender. Receiver operator curves were developed and the areas under the curve were compared between the TCS and other systems.

RESULTS: There 777,794 patients studied (BT, 91.1%; PT, 8.9%). Blunt trauma patients were older (53.6 ± 21.3 years vs. 34.4 ± 13.8 years), had higher ISS scores (11.1 ± 8.5 vs. 8.5 ± 8.9), and lower mortality (2.9% vs. 3.4%) than PT patients (p < 0.05). When assessing the entire PT and BT cohort the optimal ISS cut point was 16. The optimal ISS was between 20 and 25 for BT younger than 70 years. For those older than 70 years, the optimal BT ISS steadily declined as age increased PT's cut point was 16 or less for all ages assessed. When the injury metrics were compared by area under the curve, our novel TCS more accurately predicted mortality across all ages in both BT and PT (p < 0.001).

CONCLUSION: Injury Severity Score is a poor mortality predictor in older patients and those sustaining penetrating trauma. The age-based TCS is a superior metric for mortality prediction across all ages.

LEVEL OF EVIDENCE: Clinical outcomes, Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Keskey RC, Slidell MB, Bohr NL, et al. Novel Trauma Composite Score is superior to Injury Severity Score in predicting mortality across all ages. J Trauma Acute Care Surg. 2021. PMID: 34225345. doi:10.1097/TA.0000000000003340

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。